Lu Jun, Zhang Qi, Liang Chun-Min, Xia Shu-Jie, Zhong Cui-Ping, Wang Da-Wei
Department of Urology, Shanghai Jiao Tong University, Affiliated First People's Hospital, Shanghai 200080, China.
Asian J Androl. 2008 Nov;10(6):883-9. doi: 10.1111/j.1745-7262.2008.00431.x.
To investigate the antitumor immunity by a dendritic cell (DC) vaccine encoding secondary lymphoid chemokine gene and tumor lysate on murine prostate cancer.
DC from bone marrow of C57BL/6 were transfected with a plasmid vector expressing secondary lymphoid chemokine (SLC) cDNA by Lipofectamine 2,000 liposome and tumor lysate. Total RNA extracted from SLC+lysate-DC was used to verify the expression of SLC by reverse transcriptase-polymerase chain reaction (RT-PCR). The immunotherapeutic effect of DC vaccine on murine prostate cancer was assessed.
We found that in the prostate tumor model of C57BL/6 mice, the administration of SLC+lysate-DC inhibited tumor growth most significantly when compared with SLC-DC, lysate-DC, DC or phosphate buffer solution (PBS) counterparts (P < 0.01). Immunohistochemical fluorescent staining analysis showed the infiltration of more CD4(+), CD8(+) T cell and CD11c(+) DC within established tumor treated by SLC+lysate-DC vaccine than other DC vaccines (P < 0.01).
DC vaccine encoding secondary lymphoid chemokine and tumor lysate can elicit significant antitumor immunity by infiltration of CD4(+), CD8(+) T cell and DC, which might provide a potential immunotherapy method for prostate cancer.
研究编码二级淋巴组织趋化因子基因和肿瘤裂解物的树突状细胞（DC）疫苗对小鼠前列腺癌的抗肿瘤免疫作用。
用脂质体2000将表达二级淋巴组织趋化因子（SLC）cDNA的质粒载体转染至C57BL/6小鼠骨髓来源的DC，并加入肿瘤裂解物。从SLC+裂解物-DC中提取的总RNA用于通过逆转录-聚合酶链反应（RT-PCR）验证SLC的表达。评估DC疫苗对小鼠前列腺癌的免疫治疗效果。
我们发现，在C57BL/6小鼠的前列腺肿瘤模型中，与SLC-DC、裂解物-DC、DC或磷酸盐缓冲液（PBS）对照组相比，给予SLC+裂解物-DC最显著地抑制了肿瘤生长（P<0.01）。免疫组织化学荧光染色分析显示，与其他DC疫苗相比，SLC+裂解物-DC疫苗治疗的已建立肿瘤内浸润的CD4(+)、CD8(+)T细胞和CD11c(+)DC更多（P<0.01）。
编码二级淋巴组织趋化因子和肿瘤裂解物的DC疫苗可通过CD4(+)、CD8(+)T细胞和DC的浸润引发显著的抗肿瘤免疫，这可能为前列腺癌提供一种潜在的免疫治疗方法。
